AMEN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Amen, and what generic alternatives are available?
Amen is a drug marketed by Amarin Pharms and is included in one NDA.
The generic ingredient in AMEN is medroxyprogesterone acetate. There are twenty drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the medroxyprogesterone acetate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Amen
A generic version of AMEN was approved as medroxyprogesterone acetate by BARR on August 9th, 1996.
Summary for AMEN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 78 |
Patent Applications: | 4,461 |
Formulation / Manufacturing: | see details |
DailyMed Link: | AMEN at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for AMEN
US Patents and Regulatory Information for AMEN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amarin Pharms | AMEN | medroxyprogesterone acetate | TABLET;ORAL | 083242-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |